# Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)

> **NCT03453164** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fukushima Medical University** · enrollment: 41 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03453164
- **Lead sponsor:** Fukushima Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-28
- **Primary completion:** 2021-01-07
- **Final completion:** 2021-01-31
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03453164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03453164, "Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03453164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*